Senzo

Name

Senzo

Legal name

Senzo

Website

https://senzo.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Senzo is a Philadelphia-based bio-med company developing its proprietary Amplified Lateral Flow (ALF) diagnostic platform, which reportedly achieves over 98% accuracy versus PCR tests for point-of-care and at-home COVID-19 and influenza testing pending FDA authorization.

Ownership category

akta.pro rank

Product category

Point-of-Care Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)

akta.pro secondary industries

Multiplex Syndromic POCT Panels (Respiratory/GI/meningitis panels) (HLAHAOAJ), Point-of-Care & Decentralized Trial Testing Services (HLAGAEAK)

Keywords

• Lateral flow diagnostics
• Point-of-care testing
• Infectious disease detection
• Rapid antigen testing
• Diagnostic test platform

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Diagnostic Tests: Revenue generated from the sale of point-of-care diagnostic tests including COVID-19 and other disease tests. The company develops and manufactures diagnostic tests for at-home and point-of-care use.
2. Diagnostic Platform: Revenue model based on selling diagnostic testing platforms and associated consumables/tests. Plans to bring tests to market by 2023 following FDA approval.

Go-to-market motion2 records

Distribution channels2 records

Core offering

Senzo develops and manufactures diagnostic tests based on its proprietary Amplified Lateral Flow (ALF) platform, which enhances the accuracy of traditional lateral flow assays to over 98% versus laboratory PCR tests. The platform is being deployed for COVID-19, influenza, and other infectious disease tests, targeting both clinical point-of-care settings and at-home consumer use pending FDA Emergency Use Authorization.

Differentiator

Problem solved

Functional benefit

Brands

• ALF (Amplified Lateral Flow): High-accuracy, low-cost point-of-care diagnostic platform that compares favorably to PCR tests, achieving over 98% accuracy.

Products and services

• ALF (Amplified Lateral Flow) Diagnostic Platform High-accuracy, low-cost point-of-care diagnostic platform that enhances lateral flow test accuracy to provide laboratory PCR-level diagnostics for at-home and point-of-care use, including COVID-19 and influenza tests. The platform achieved over 98% accuracy against PCR tests.

Quantifiable outcome

• Over 98% accuracy against PCR tests

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators4 records

Direct peers

• LumiraDx: Direct peer developing microfluidic point-of-care diagnostic platforms targeting rapid, PCR-comparable results at low cost across infectious disease menu - directly comparable technology and use case to Senzo's ALF platform.
• Mesa Labs (now Eurofins) - Accula platform: PCR-quality point-of-care rapid molecular diagnostic platform directly comparable to Senzo's value proposition of delivering laboratory-grade accuracy in a portable, decentralized format.
• Cue Health: Direct-to-consumer molecular diagnostic company offering PCR-quality at-home and point-of-care testing - exact same GTM motion (POC + DTC) and accuracy-vs-PCR positioning as Senzo.
• OraSure Technologies: Develops rapid diagnostic tests including at-home and point-of-care infectious disease products (InteliSwab, OraQuick) - direct peer in lateral-flow-based POC and at-home rapid diagnostics.
• Atomo Diagnostics: Developer of integrated rapid diagnostic test devices for point-of-care and at-home use, including COVID-19 tests - comparable integrated device approach and POC/at-home GTM motion.

Broad incumbents

• Abbott (Rapid Diagnostics - BinaxNOW, ID NOW): Largest incumbent in rapid POC diagnostics with BinaxNOW lateral flow and ID NOW molecular platforms - sets the competitive ceiling Senzo must beat on accuracy and cost across the same COVID-19 and influenza testing menus.
• QuidelOrtho (QuickVue, Sofia): Major incumbent in lateral flow and immunoassay-based POC diagnostics (QuickVue, Sofia) - directly comparable product format (lateral flow assays for COVID-19, flu, RSV) where Senzo claims accuracy improvement.
• Becton Dickinson (BD Veritor System): Incumbent player in POC rapid antigen testing (BD Veritor Plus) for COVID-19, influenza, and RSV - large-scale competitor that Senzo's ALF platform aims to outperform on accuracy.
• Cepheid (Danaher): Gold-standard PCR-based POC molecular diagnostics (GeneXpert) - Senzo's value proposition is explicitly framed as PCR-comparable accuracy at lower cost and faster turnaround, making Cepheid the performance benchmark.

Emerging players

• Mologic (now part of Global Access Health): Diagnostic developer with lateral flow and rapid test expertise targeting infectious disease and global health applications - emerging peer in low-cost rapid diagnostics that overlaps with Senzo's POC strategy.

Market position

Customer concentration

• Xx.com/Orphidia
• Facebookfacebook.com/orphidia

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds8 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Senzo